Pregabalin for painful diabetic peripheral neuropathy: Commentary

Nature Clinical Practice Endocrinology and Metabolism

Volumn 5, Issue 1, 2009, Pages 14-15

  Rogers, Lee C ^a   Armstrong, David G ^b  

^a BROADLAWNS MEDICAL CENTER   (United States)

^b UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; CALCIUM CHANNEL; DULOXETINE; NONSTEROID ANTIINFLAMMATORY AGENT; OPIATE; PLACEBO; PREGABALIN;

ANALGESIA; CALCIUM TRANSPORT; CLINICAL TRIAL; DIABETIC NEUROPATHY; DIZZINESS; DRUG BINDING; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; HUMAN; NOTE; PAIN; PAIN ASSESSMENT; PERIPHERAL EDEMA; PRIORITY JOURNAL; SLEEP DISORDER; SOMNOLENCE;

EID: 57649176608     PISSN: 17458366     EISSN: 17458374     Source Type: Journal    
DOI: 10.1038/ncpendmet1019     Document Type: Note

References (7)

1. Dyck PJ et al. (1993) The prevalence by staged severity of various types of diabetic neuropathy, retinopathy, and nephropathy in a population-based cohort: the Rochester Diabetic Neuropathy Study. Neurology 43: 817-824
2. Boulton AJ et al. (2005) Diabetic neuropathies: a statement by the American Diabetes Association. Diabetes Care 28: 956-962
3. + channel alpha2delta ligands: novel modulators of neurotransmission. Trends Pharmacol Sci 28: 75-82
4. Freeman R et al. (2008) Efficacy, safety, and tolerability of pregabalin treatment for painful diabetic peripheral neuropathy: findings from seven randomized, controlled trials across a range of doses. Diabetes Care 31: 1448-1454
5. Rogers LC et al. (2004) Treatment of painful diabetic neuropathy: a review of the most efficacious pharmacologic treatments. Practical Diabetes Int 21: 301-306
6. Galer BS et al. (2000) Painful diabetic polyneuropathy: epidemiology, pain description, and quality of life. Diabetes Res Clin Pract 47: 123-128
7. Sullivan SD et al. (2002) Health state preference assessment in diabetic peripheral neuropathy. Pharmacoeconomics 20: 1079-1089